Bridging the Divide: Student Grand Rounds at the Interface of Basic Science and Clinical Medicine

Marie A Hollenhorst1, David A Braun, Christopher R Burtner

  • 1M.A. Hollenhorst is clinical instructor, Division of Pathology, Stanford University School of Medicine, Stanford, California; ORCID: https://orcid.org/0000-0002-2237-6645. D.A. Braun is a fellow, Hematology-Oncology, Massachusetts General Hospital Cancer Center and Dana-Farber Cancer Institute, Boston, Massachusetts. C.R. Burtner is assistant professor, Department of Biology, Roger Williams University, Bristol, Rhode Island. I. Cajigas is a sixth-year resident, Department of Neurological Surgery, University of Miami Leonard M. Miller School of Medicine and Jackson Memorial Hospital, Miami, Florida. A.C. Cunningham-Bussel is a fellow, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Massachusetts. P.Ö. Eser is a research fellow, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. C.S. Nabel is a fellow, Hematology-Oncology, Massachusetts General Hospital Cancer Center and Dana-Farber Cancer Institute, Boston, Massachusetts. F.D. Tsai is a fellow, Hematology-Oncology, Massachusetts General Hospital Cancer Center and Dana-Farber Cancer Institute, Boston, Massachusetts. L.D. Weeks is a fellow, Hematology-Oncology, Massachusetts General Hospital Cancer Center and Dana-Farber Cancer Institute, Boston, Massachusetts. T. Michel is professor of medicine and co-director, Leder Human Biology and Translational Medicine Program, Biological and Biomedical Sciences, Harvard Medical School, as well as senior physician in medicine, Brigham and Women's Hospital, Boston, Massachusetts. M.A. Yialamas is associate program director, Internal Medicine Residency, Brigham and Women's Hospital, and assistant professor of medicine, Harvard Medical School, Boston, Massachusetts.

Abstract

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
883
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
195
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
298
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
624
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
205